Physician profile
Tamara E Carey
NPI 1366991424
$7,391.78
in general payments reported to CMS, 2019-2025
35 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,156 · 2022: $1,173 · 2023: $1,740 · 2024: $2,120 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,942.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.03 | 2021-2023 | |
| Tempus Ai, INC | $460.32 | 2024-2025 | Tempus Pixel |
| Solventum Corporation | $429.85 | 2024-2025 | V.A.C. Veraflo, Activ.A.C., V.A.C.Ulta |
| Gilead Sciences, INC. | $397.29 | 2022-2025 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $389.75 | 2022-2024 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $333.12 | 2021-2024 | Opdivo, Opdualag |
| Intera Oncology, INC | $331.69 | 2024-2025 | Intera |
| Angiodynamics, INC. | $316.11 | 2022-2025 | Nanoknife |
| Idorsia Pharmaceuticals US INC | $315.03 | 2024 | Tryvio |
| Genentech USA, INC. | $262.95 | 2021-2023 | Lunsumio, Polivy |
| Jazz Pharmaceuticals INC. | $249.78 | 2021-2022 | |
| Astellas Pharma US INC | $247.21 | 2025 | Padcev, Vyloy |
| Genzyme Corporation | $245.94 | 2021-2022 | |
| Evoke Pharma, INC. | $226.96 | 2023-2024 | Gimoti |
| Novo Nordisk INC | $204.26 | 2022-2024 | Wegovy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $185.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $170.06 | 2022-2023 | Keytruda |
| Glaxosmithkline, LLC. | $168.97 | 2023-2024 | Jemperli |
| Amgen INC. | $141.12 | 2022 | |
| Genentech, INC. | $136.80 | 2023 | Tecentriq, Avastin |
| Sobi, INC | $120.27 | 2022 | |
| Sumitomo Pharma America, INC. | $120.00 | 2024 | Gemtesa |
| G1 Therapeutics, INC. | $116.44 | 2021 | |
| Corcept Therapeutics | $107.39 | 2024 | Korlym |
| Alcresta Therapeutics, INC. | $107.39 | 2025 | Relizorb |
| Kite Pharma, INC. | $107.10 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $100.49 | 2023 | Crysvita |
| Kci USA, INC. | $99.54 | 2023 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Otsuka America Pharmaceutical, INC. | $98.81 | 2023 | Nuedexta |
| Puma Biotechnology, INC. | $88.67 | 2025 | |
| Lilly USA, LLC | $86.18 | 2023 | Verzenio |
| Epizyme, INC. | $85.99 | 2022 | |
| Daiichi Sankyo INC. | $73.87 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.